FDA Approves Qualified Health Claim for Resistant Starch, Type 2 Diabetes
Foods and beverages, including bakery, nutrition bar, and cereal and pasta products, can now use the claim.
Photo © iStockphoto.com/evgenyb
Ingredion Inc.’s (Westchester, IL) Hi-Maize high-amylose maize resistant starch has a newly approved qualified health claim from FDA linking the ingredient with a reduction in the risk of type 2 diabetes.
Foods and beverages-including bakery, nutrition bar, and cereal and pasta products-using Hi-Maize can now use the claims:
- “High-amylose maize resistant starch may reduce the risk of type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim.”
- “High-amylose maize resistant starch, a type of fiber, may reduce the risk of type 2 diabetes. FDA has concluded that there is limited scientific evidence for this claim.”
According to Ingredion, FDA based its assessment on eight clinical trials showing the positive impact of Hi-Maize on insulin sensitivity and other biomarkers related to blood sugar.
“We believe the new qualified health claim is a positive development for consumers as it provides another pragmatic approach to potential diabetes risk reduction through everyday foods,” said Lorraine Niba, PhD, global director, nutrition springboard, for Ingredion.
Also read:
Acacia Gum Granted EU Health Claim for Glycemic Reduction
Jennifer Grebow
Editor-in-Chief
Nutritional Outlook magazine
jennifer.grebow@ubm.com
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Survey finds a lack of enthusiasm about AI technology among food and beverage consumers
December 12th 2024The survey, commissioned by Ingredient Communications and conducted by SurveyGoo, found that 83% of respondent agreed that companies should declare on product labels when a product has been designed or manufactured with the assistance of AI technology.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
